Open AccessS921 Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings from ROTARY-1
Author(s) -
Noa Krugliak Cleveland,
Benjamin Chastek,
Sabyasachi Ghosh,
Ninfa Candela,
Timothy Bancroft,
Tao Fan,
Kandavadivu Umashankar,
David T. Rubin
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000777216.13581.16
Subject(s) - medicine , vedolizumab , adalimumab , infliximab , discontinuation , inflammatory bowel disease , ustekinumab , ulcerative colitis , persistence (discontinuity) , crohn's disease , gastroenterology , golimumab , disease , geotechnical engineering , engineering